Showing papers by "Mark Pimentel published in 2002"
TL;DR: In conclusion, phase III is reduced in subjects with IBS and SIBO, and eradication of bacterial overgrowth seems to result in some normalization of motility.
Abstract: We have recently described an association between irritable bowel syndrome (IBS) and abnormal lactulose breath test, suggesting small intestinal bacterial overgrowth (SIBO). However, the mechanism by which SIBO develops in IBS is unknown. In this case-control study we evaluate the role of small intestinal motility in subjects with IBS and SIBO. Small intestinal motility was studied in consecutive IBS subjects with SIBO on lactulose breath test. After fluoroscopic placement of an eight-channel water-perfused manometry catheter, 4-hr fasting recordings were obtained. Based on this, the number and duration of phase III was compared to 30 control subjects. To test whether there was a relationship between the motility abnormalities seen and the SIBO status of the patient at the time of the motility, subjects with a breath test within 5 days of the antroduodenal manometry were also compared. Sixty-eight subjects with IBS and SIBO were compared to controls. The number of phase III events was 0.7 +/- 0.8 in IBS subjects and 2.2 +/- 1.0 in controls (P < 0.000001). The duration of phase III was 305 +/- 123 sec in IBS subjects and 428 +/- 173 in controls (P < 0.001). Subjects whose SIBO was still present at the time of manometry had less frequent phase III events than subjects with eradicated overgrowth (P < 0.05). In conclusion, phase III is reduced in subjects with IBS and SIBO. Eradication of bacterial overgrowth seems to result in some normalization of motility.
150 citations
Patent•
16 Apr 2002TL;DR: In this paper, a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject is presented. But, the method of determining the relative severity of SIBO or SIBO caused conditions is not discussed.
Abstract: Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.
141 citations
TL;DR: There is a higher prevalence of IBS in subjects with GERD compared with subjects without GERD, and this prevalence was compared between GERD and non-GERD subjects.
Abstract: GoalsTo determine the prevalence of irritable bowel syndrome (IBS) in subjects with gastroesophageal reflux disease (GERD) compared with non-GERD controls.StudyTwo hundred subjects were identified from a list of Cedars-Sinai Medical Foundation patients and gastroenterology motility practice
69 citations
TL;DR: In this article, the authors found an intriguing relationship between the use of antibiotics and the development of functional bowel symptoms likened to irritable bowel syndrome (IBS) and found that there was an increased incidence of functional GI symptoms relative to controls.
6 citations
1 citations
Patent•
16 Apr 2002TL;DR: In this paper, pharmaceutically acceptable compositions, which may comprise a stabilizer of mast cell membranes in the lumenal wall of the small intestine, in an amount sufficient to inhibit a mast cell-mediated immune response in a human subject, for use as a medicament for treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in which the presence of SIBO has been detected.
Abstract: The present invention concerns pharmaceutically acceptable compositions, which may comprise a stabilizer of mast cell membranes in the lumenal wall of the small intestine, in an amount sufficient to inhibit a mast cell-mediated immune response in a human subject, for use as a medicament for treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject in which the presence of SIBO has been detected.
1 citations
Patent•
16 Apr 2002TL;DR: In this article, a method of detecting small intestinal bacterial overgrowth (SIBO) in a human subject is described. But the method is not suitable for the detection of small intestinal bacteria.
Abstract: Disclosed is a method of detecting small intestinal bacterial overgrowth (SIBO) in a human subject. The method involves detecting the relative amounts of methane, hydrogen, and at least one sulfur-containing gas in a gas mixture exhaled by said human subject, after said human subject has ingested a controlled quantity of a substrate, said gas mixture being at least partially produced by the intestinal microflora of said human subject. Kits for use in such detection methods are also disclosed.